Tamilife® 75 mg Capsules

Revive. Survive. Thrive.

Tamilife is an effective antiviral medication containing Oseltamivir Phosphate, indicated for the treatment and prevention of Influenza A and B. It works by inhibiting viral replication, reducing symptom severity, shortening disease duration, and lowering the risk of influenza-related complications when administered promptly.

Tamilife is clinically proven, well-tolerated, and aligned with international treatment guidelines, making it a reliable choice for managing acute influenza infections across different patient populations

Key Ingredients and Benefits

Oseltamivir Phosphate (75 mg)

Pharmacological Class: Antiviral – Neuraminidase Inhibitor

Key Benefits:

• Inhibits Influenza Virus Replication:
  Oseltamivir selectively blocks neuraminidase enzymes on the surface of Influenza A and B viruses, preventing the release and spread of newly formed viral particles.

• Reduces Duration of Symptoms:
  Clinical evidence shows a reduction in influenza symptom duration by approximately 0.5–1.0 day when treatment is initiated within 48 hours of symptom onset.

• Decreases Severity of Illness:
  Helps alleviate key influenza symptoms such as fever, cough, sore throat, headache, and muscle pain.

• Prevents Disease Progression:
  Limits viral load and reduces the risk of complications, including pneumonia, bronchitis, and otitis media.

• Effective for Treatment and Prevention:
  Suitable for both active treatment of influenza and post-exposure prophylaxis in high-risk or exposed individuals.

• Well-Tolerated Antiviral Therapy:
  Demonstrates a favorable safety profile when used as recommended, making it appropriate for a wide range of patient populations under medical supervision.

How Tamilife Works?

Tamilife contains Oseltamivir Phosphate, a targeted antiviral agent that interferes with the influenza virus life cycle and limits its spread within the body.

1. Inhibition of Viral Release

Oseltamivir selectively inhibits neuraminidase enzymes present on the surface of Influenza A and B viruses. These enzymes are essential for the release of newly formed viral particles from infected host cells. By blocking neuraminidase activity, Tamilife prevents the virus from spreading to healthy respiratory cells.

2. Reduction of Viral Replication

By limiting viral release, Tamilife reduces overall viral replication in the respiratory tract. This helps control infection progression, especially when treatment is initiated within 48 hours of symptom onset.

3. Symptom Relief and Faster Recovery

Lower viral load leads to reduced inflammation and milder clinical symptoms, including fever, cough, sore throat, and muscle pain, contributing to a shorter duration of illness.

4. Prevention of Complications

By controlling viral spread early, Tamilife decreases the risk of influenza-related complications such as pneumonia, bronchitis, and secondary bacterial infections, particularly in high-risk patients.

Why Choose Tamilife?

• Clinically Proven Antiviral Therapy for Influenza A & B

• Reduces Symptom Duration and Severity

• Lowers Risk of Serious Respiratory Complications

• Well-Tolerated Safety Profile

• Trusted Treatment Option aligned with global influenza management guidelines

• High Manufacturing Quality Standards